HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has ...
Aug 1 (Reuters) - Bio-Rad Laboratories (BIO.N), opens new tab cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.
In a report released yesterday, Brandon Couillard from Wells Fargo maintained a Hold rating on Bio-Rad Laboratories (BIO – Research Report), with a price target of $360.00. The company’s shares closed ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based ...
Bio-Rad Laboratories ( (BIO)) has realeased its Q3 earnings. Here is a breakdown of the information Bio-Rad Laboratories presented to its investors. Bio-Rad Laboratories, Inc., based in Hercules, ...
Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and ...
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Bio-Rad Laboratories (BIO) one of those stocks right now? A quick glance at the ...
Good afternoon everyone, and welcome to today's Bio-Rad First Quarter 2024 Earnings Results Conference Call. At this time, all lines are in a listen-only mode. Later, you will have the opportunity to ...
Thank you for standing by. My name is Prila [ph] and I will be your conference operator today. At this time, I would like to welcome everyone to the Bio-Rad Fourth Quarter and Full Year 2024 Results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback